Abstract
摘要
相似文献
1
Update: hemophilia surveillance project.更新：血友病监测项目。
J Okla State Med Assoc. 1997 Feb;90(2):72.
2
3
Safety of therapeutic products used for hemophilia patients.用于血友病患者的治疗产品的安全性。
MMWR Morb Mortal Wkly Rep. 1988 Jul 29;37(29):441-4, 449-50.
4
[Incidence of hemophilia in Poland and current problems of its treatment].[波兰血友病的发病率及其当前治疗问题]
Acta Haematol Pol. 1987 Jan-Jun;18(1-2):93-5.
5
[Prevalence of HCV, HBV and HIV infections among severe Polish haemophiliacs].[波兰重度血友病患者中丙型肝炎病毒、乙型肝炎病毒和艾滋病病毒感染的患病率]
Przegl Epidemiol. 2008;62(2):415-23.
6
Prevalence of hepatitis C virus infection among patients with inherited bleeding disorders in Newfoundland.纽芬兰遗传性出血性疾病患者中丙型肝炎病毒感染的患病率。
Can Commun Dis Rep. 1992 Jun 26;18(12):91-2, 95.
7
Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment.荷兰血友病患者中的丙型肝炎感染：一项关于患病率和抗病毒治疗的全国性横断面研究。
Haemophilia. 2005 May;11(3):270-5. doi: 10.1111/j.1365-2516.2005.01083.x.
8
Leads from the MMWR. Safety of therapeutic products used for hemophilia patients.来自《发病率与死亡率周报》。血友病患者使用的治疗产品的安全性。
JAMA. 1988 Aug 19;260(7):901-3.
9
Hemophilia now reportable for purposes of special state survey.为进行特殊的州调查，血友病现需上报。
J Okla State Med Assoc. 1994 Dec;87(12):561.
10
Blood-borne pathogens routine surveillance system report.
Can Commun Dis Rep. 2002 Jul;28 Suppl 2:1-59.
Zotero 插件